Resmed (RMD) Liabilities and Shareholders Equity (2016 - 2025)
Resmed (RMD) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $8.5 billion as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 19.07% year-over-year to $8.5 billion, compared with a TTM value of $32.6 billion through Dec 2025, up 53.29%, and an annual FY2025 reading of $8.2 billion, up 18.95% over the prior year.
- Liabilities and Shareholders Equity was $8.5 billion for Q4 2025 at Resmed, up from $8.3 billion in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $8.5 billion in Q4 2025 and bottomed at $4.6 billion in Q1 2021.
- Average Liabilities and Shareholders Equity over 5 years is $6.4 billion, with a median of $6.7 billion recorded in 2023.
- The sharpest move saw Liabilities and Shareholders Equity grew 1.67% in 2021, then skyrocketed 41.0% in 2022.
- Year by year, Liabilities and Shareholders Equity stood at $4.7 billion in 2021, then skyrocketed by 41.0% to $6.7 billion in 2022, then rose by 3.43% to $6.9 billion in 2023, then rose by 3.42% to $7.1 billion in 2024, then increased by 19.07% to $8.5 billion in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for RMD at $8.5 billion in Q4 2025, $8.3 billion in Q3 2025, and $8.2 billion in Q2 2025.